DnB Asset Management
OCUL icon

DnB Asset Management’s Ocular Therapeutix OCUL Stock Holding History

DnB Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Sell
52,722
-387
-0.7% -$3.51K ﹤0.01% 783
2026
Q1 		$450K Buy
53,109
+8,658
+19% +$82.5K ﹤0.01% 800
2025
Q4 		$540K Buy
+44,451
New +$540K ﹤0.01% 675

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DnB Asset Management's OCUL Position: Q2 2026 in Review

DnB Asset Management reduced its Ocular Therapeutix (OCUL) stake by 0.73% in Q2 2026, selling an estimated $3.51K and leaving 52,722 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #783.

DnB Asset Management first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $540K in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • DnB Asset Management held 52,722 shares of Ocular Therapeutix worth $518K as of Q2 2026.
  • DnB Asset Management sold 387 Ocular Therapeutix shares in Q2 2026, an estimated $3.51K.
  • Ocular Therapeutix made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #783 holding.
  • DnB Asset Management first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • DnB Asset Management's Ocular Therapeutix position peaked at $540K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.